[Clinical studies on cefmetazole in respiratory infections].
Cefmetazole (CMZ) was used for the treatment of respiratory infections in 10 cases; six cases of bronchopneumonia, 2 cases of acute exacerbation of chronic pulmonary emphysema or bronchitis disease, 1 case of acute exacerbation of chronic respiratory failure and 1 case of lung abscess. CMZ was administered by intravenous drip infusion at a daily dose of 2 to 4 g for 5 to 24 days. Intramuscular injection of gentamicin was combined in 2 cases. Clinical results were as follows; excellent in 6 cases, good in 2 cases, fair in 1 case and poor in 1 case. As to the side effects of the drug, allergic reaction with fever and eosinophilia was observed in 1 case. This side effect disappeared immediately after cessation of CMZ. In view of the above, CMZ may be considered to be a clinically useful antibiotic against respiratory infections.
D000328:Adult; D000368:Aged; D015311:Cefmetazole; D002511:Cephalosporins / Q000627:therapeutic use*; D002513:Cephamycins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012141:Respiratory Tract Infections / Q000188:drug therapy*
D002511:Cephalosporins; D002513:Cephamycins; D015311:Cefmetazole